English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BACKGROUND Chimeric antigen receptor (CAR) modified T cell therapy is a promising treatment strategy for cancer therapy. We developed IL-8 receptor-linked CD70CAR (8R-70CAR), aiming to enhance T-cell intratumoral trafficking and persistence, guided by IL-8-secreting tumors. The preclinical results show that 8R-70CAR T cells induce complete tumor regression and long-lasting antitumor immunity, which necessitate further clinical development of this technology. OBJECTIVE To assess the toxicity of 8R-70CAR T cells, evaluate in vitro tumor recognition and expansion of the 8R-70CAR T cells, and develop clinically compliant SOPs for the CAR T cell manufacture. METHODS The m8R-70CAR (mouse), h8R-70CAR (human), and control CAR were constructed. Toxicology: C57BL/6J mice were intravenously injected with or without 2x106 m8R-70CAR T cells after total body irradiation (5Gy). The body weight, clinical signs, hematology, serum chemistry, serum cytokines, gross pathology, and histopathology of 12 vital organs were evaluated. Tumor recognition: T cells derived from GBM patients were transduced with h8R-70CAR and then co-cultured with CD70+ glioblastoma. INF-g production was measured. Ex vivo expansion: The G-Rex system was utilized for CAR T cell production, and the expansion of h8R-70CAR T cells was assessed by cell count. RESULTS No CAR T cell-related toxicity was observed in mouse study. In addition to a robust antitumor reactivity, the h8R-70CAR T cells present an auto-stimulative property that elicits greater ex vivo expansion compared to other CAR T cells tested. An approximately 1200-fold expansion was achieved during the 2 weeks CAR T cell production without additional stimulation, which allows production of the CAR T cells on a clinical trial scale using &amp;lt; 100mL of whole blood. CONCLUSION The 8R-70CAR T cells are effective, auto-stimulative, and safe. These properties are fundamental for successful clinical applications in cancer treatment. A phase I trial using the 8R-70CAR T cells in newly diagnosed GBM will be initiated soon.

IMMU-38. PRECLINICAL VALIDATION AND MANUFACTURE OF IL-8 RECEPTOR-MODIFIED CD70 CAR T CELLS FOR CLINICAL TRIAL